Long lasting response to second-line everolimus in kidney cancer

Table 1 Food and Drug Administration and European Medicines Agency drug labels

Drug	FDA approval in kidney cancer for	EMEA approval in kidney cancer for
Everolimus	Treatment of patients with advanced RCC after failure of treatment with sunitinib or sorafenib	Advanced renal cell carcinoma (kidney cancer that has started to spread). It is used when the cancer has progressed during or after previous treatment with a medicine that targets vascular endothelial growth factor
Sunitinib	The treatment of advanced renal cell carcinoma	Metastatic renal cell carcinoma, a type of kidney cancer that has spread to other organs
Bevacizumab	The treatment of metastatic renal cell carcinoma in combination with interferon-α	Advanced or metastatic kidney cancer, in combination with interferon-α-2a
Sorafenib	The treatment of patients with advanced renal cell carcinoma	Advanced renal cell carcinoma when anticancer treatment with interferon-α or interleukin-2 has failed or cannot be used
Temsirolimus	The treatment of advanced renal cell carcinoma	advanced renal cell carcinoma. “Advanced” means that the cancer has started to spread
Pazopanib	The treatment of patients with advanced renal cell carcinoma	Advanced renal cell carcinoma. It is used in patients who have not received any previous treatment or in patients who have already been treated for their advanced disease with anticancer medicines called “cytokines”. “Advanced” means that the cancer has started to spread.
Axitinib	Treatment of advanced renal cell carcinoma after failure of one prior systemic therapy	Treatment of advanced renal cell carcinoma when treatment with Sutent (sunitinib) or “cytokines” has failed

EMEA: European Medicines Agency; FDA: Food and Drug Administration; RCC: Renal cell carcinoma.